medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2004, Number 1

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2004; 17 (1)

Results in the treatment in 91tuberculosis resistant patients at the National Institute of Respiratory Diseases: 2001-2003

Salazar LMA, Torres CA, Valdez VRR, López SE, Villarreal VH, Quiñónez FF, Báez SR

Language: Spanish
References: 22
Page: 15-21
PDF size: 63.51 Kb.


ABSTRACT

Background: Tuberculosis (TB) persists as a public health world-wide problem. The principal human concern is to cure, relieve the suffering and reduce the mortality caused by this disease. A serious problem is the increasing prevalence of multidrug-resistant tuberculosis which contributes to the failure to erradicate TB. This requires an approach based on political, social and economic responsibility focused on the patient for TB control. Methods: We analyzed ninety-one files of patients with multidrug-resistant tuberculosis that were referred to the Institute by health services of different states and Mexico City. The cases were classified according to the criteria established by the World Health Organization (WHO). Results: In Group 1, the success rate was 63%, in Group 2 was 100% and in Group 3 was 41.8%. In the three groups the rate of success was 49%. After analyzing data by state, the worst results were from Morelos with 0%, Puebla 25%, Mexico state 38% and Mexico City with 58% (7 of 12). The best results were from Veracruz with 77%, Guerrero 75% and Chiapas 71%. This makes evident that the distance from the reference center is not a risk factor for treatment failure. Conclusions: It is imperative to prevent new cases of multidrug-resistant tuberculosis by increasing the rate of cure and to reduce the dissemination of the disease by efficiently treating all new cases.


REFERENCES

  1. Anti-tuberculosis Drug Resistance in the World. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. WHO/TB/97.229.

  2. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Jae KS, Reniero A, et al. Goblal Trenes in Resistance to Antituberculosis Drugs. N Engl J Med 2001;344:1294-1303.

  3. White VL, Moore-Gillon. Resource Implications of Patients with Multidrug-resistant Tuberculosis. Thorax 2000;55:962-963.

  4. Zumia A, Grange JM. Multidrug-resistant Tuberculosis-can the Tide be Turned? Lancet Infect Dis 2001;1:199-202.

  5. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. World Health Organization-Geneva, 2003.

  6. Báez SR, Pérez PR, Salazar LM. Discrepancias entre los datos ofrecidos por la Secretaría de Salud y la Organización Mundial de la Salud sobre tuberculosis en México, 1981-1998. Salud Publica Mex 2003;45:78-83.

  7. Grancih RM, Balandrano S, Santaella AJ, Binkin NJ, Castro KG, Márquez-Fiol A, et al. Survey of Drug Resistance of Mycobacterium tuberculosis in 3 Mexican States, 1997. Arch Intern Med 2000;160:639-644.

  8. García-García ML, Ponce de León A, Jiménez-Corona E, Jiménez-Corona A, Palacios-Martínez M, Balandrano-Campos S, et al. Clinical Consequences and Transmissibility of Drug-resistant Tuberculosis in Southern Mexico. Arch Intern Med 2000;160:630-636.

  9. Espinal MA, Kim SJ, Suárez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard Short Course Chemotherapy for Drug Resistant Tuberculosis. Treatment Outcomes in 6 Countries. JAMA 2000;283:2968-2974.

  10. Bastian I, Rigouts L, van Deun A, Portaels F. Directly Observed Treatment, Short-course Strategy and Multidrug-resistant Tuberculosis: are any Modifications Required? Bull World Health Organ 2000;78:238-251.

  11. Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G, et al. Feasibility and Cost-effectiveness of Standardized Second-line Drug Treatment for Chronic Tuberculosis Patients: a National Cohort Study in Peru. Lancet 2002;359:1980-1989.

  12. Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multidrug-resistant Tuberculosis (MDR-TB). World Health Organization. WHO/CDS/TB/2000.

  13. Farmer PE, Kim JY. Community-based Approaches to the Control of Multi-drug-resistant Tuberculosis: Introducing “DOTS-plus”. Brit Med J 1998;317:671-674.

  14. Iseman MD. MDR-TB and the Developing World- a Problem no Longer to be Ignored: the WHO Announces “DOTS Plus” Strategy. Int J Tuberc Lung Dis 1998;2:867.

  15. Park SK, Kim CT, Song SD. Outcome of Chemotherapy in 107 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin. Int J Tuberc Lung Dis 1988;2:877-884.

  16. Tahaoglu K, Torun T, Sevim T, Güliz KA, Karasulu L, Ozmen KN. The Treatment of Multidrug-resistant Tuberculosis in Turkey. N Engl J Med 2001;345:170-174.

  17. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based Therapy for Multidrug-resistant Tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-128.

  18. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh R. Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin. N Engl J Med 1993;328:527-532.

  19. Farmer P, Bayona M, Becerra M, Furin J, Henry C, Hiatt J, et al. The Dilemma of MDR-TB in the Global Era. Int J Tuberc Lung Dis 1998;2:869-876.

  20. What is DOTS? A Guide to Understanding the WHO-recommended TB Control Strategy Known as DOTS. 1999. WHO/CDS/CPC/TB99.270.

  21. Dye C, Williams BG. Criteria for the Control of Drug-resistant Tuberculosis. Proc Natl Acad Sci USA 2000;97:8180-8185.

  22. Enarson DA. Resistance to Antituberculosis Medications. Hard Lessons to Learn. Arch Intern Med 2000;160: 581-582.




2020     |     www.medigraphic.com